483
Rachel A. Kuperman, M.D.FDA 483 - Rachel A. Kuperman, M.D. - June 27, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Rachel A. Kuperman, M.D., a clinical investigator in Paramount, CA, revealed significant deficiencies in the conduct of clinical investigations. Observations included failures to follow the investigational plan, inadequate investigational drug disposition records, and a lack of legally effective informed consent for subjects. These findings indicate serious non-compliance with regulatory requirements for clinical trials.
Open in Dashboard
ID · 6245cd8d-f33e-43a5-a4f5-b21b37f95998